Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload

Journal of the American Heart Association

Volumn 3, Issue 4, 2014, Pages

  Kapur, Navin K ^a   Qiao, Xiaoying ^a   Paruchuri, Vikram ^a   Mackey, Emily E ^a   Daly, Gerard H ^a   Ughreja, Kishan ^a   Morine, Kevin J ^a   Levine, Jonathan ^a   Aronovitz, Mark J ^a   Hill, Nicholas S ^a   Jaffe, Iris Z ^a   Letarte, Michelle ^b   Karas, Richard H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cardiac remodeling; Fibrosis; Heart failure; Pulmonary hypertension; Right ventricle

Indexed keywords

CALCINEURIN; ENDOGLIN; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; CELL SURFACE RECEPTOR; ENDOGLIN PROTEIN, MOUSE; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MESSENGER RNA; SIGNAL PEPTIDE; TGFB1 PROTEIN, HUMAN; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, HUMAN; TRPC6 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL TRANSFORMATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; HEART HEMODYNAMICS; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RIGHT VENTRICULAR PRESSURE OVERLOAD; SIGNAL TRANSDUCTION; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; ANIMAL; CYTOLOGY; DISEASE MODEL; FIBROBLAST; GENETICS; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY;

ACTINS; ANIMALS; ANTIGENS, CD; CALCINEURIN; DISEASE MODELS, ANIMAL; FIBROBLASTS; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MYOFIBROBLASTS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1; TRPC CATION CHANNELS; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84939462015     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.000965     Document Type: Article

References (54)

1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573-1619.
2. Haddad F, Peterson T, Fuh E, Kudelko KT, de Jesus Perez V, Skhiri M, Vagelos R, Schnittger I, Denault AY, Rosenthal DN, Doyle RL, Zamanian RT. Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail. 2011;4:692-699.
3. Rain S, Handoko ML, Trip P, Gan CT, Westerhof N, Stienen GJ, Paulus WJ, Ottenheijm CA, Marcus JT, Dorfmüller P, Guignabert C, Humbert M, Macdonald P, Dos Remedios C, Postmus PE, Saripalli C, Hidalgo CG, Granzier HL, Vonk-Noordegraaf A, van der Velden J, de Man FS. Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation. 2013;128:2016-2025.
4. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164-172.
5. Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, Jiang R, Roger VL. Pulmonary pressures and death in heart failure a community study. J Am Coll Cardiol. 2012;59:222-231.
6. Kapur NK, Wilson S, Yunis AA, Qiao X, Mackey E, Paruchuri V, Baker C, Aronovitz MJ, Karumanchi SA, Letarte M, Kass DA, Mendelsohn ME, Karas RH. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation. 2012;125:2728-2738.
7. Maring JA, Trojanowska M, ten Dijke P. Endoglin in fibrosis and scleroderma. Int Rev Cell Mol Biol. 2012;297:10.
8. Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res. 2007;74:207-212.
9. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130-135.
10. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753-791.
11. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. 2010;70:4141-4150.
12. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-649.
13. Kapur NK, Heffernan KS, Yunis AA, Parpos P, Kiernan MS, Sahasrabudhe NA, Kimmelstiel CD, Kass DA, Karas RH, Mendelsohn ME. Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am J Cardiol. 2010;106:1770-1776.
14. Malhotra R, Paskin-Flerlage S, Zamanian RT, Zimmerman P, Schmidt JW, Deng DY, Southwood M, Spencer R, Lai CS, Parker W, Channick RN, Morrell NW, Elliott CG, Yu PB. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ. 2013;3:369-380.
15. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP. Defective angiogenesis in mice lacking endoglin. Science. 1999;284:1534-1537.
16. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest. 1999;104:1343-1351.
17. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94:110-118.
18. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
19. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun. 2004;322:1178-1191.
20. Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA, Olson EN. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest. 2006;116:3114-3126.
21. Koitabashi N, Aiba T, Hesketh GG, Rowell J, Zhang M, Takimoto E, Tomaselli GF, Kass DA. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol. 2010;48:713-724.
22. Patel A, Sharif-Naeini R, Folgering JR, Bichet D, Duprat F, Honoré E. Canonical TRP channels and mechanotransduction: from physiology to disease states. Pflugers Arch. 2010;460:571-581.
23. Wu X, Eder P, Chang B, Molkentin JD. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc Natl Acad Sci USA. 2010;107:7000-7005.
24. Eder P, Molkentin JD. TRPC channels as effectors of cardiac hypertrophy. Circ Res. 2011;108:265-272.
25. Thodeti CK, Paruchuri S, Meszaros JG. A TRP to cardiac fibroblast differentiation. Channels (Austin). 2013;7:211-214.
26. Davis J, Burr AR, Davis GF, Birnbaumer L, Molkentin JD. A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo. Dev Cell. 2012;23:705-715.
27. Kapur NK, Paruchuri V, Aronovitz MJ, Qiao X, Mackey EE, Daly GH, Ughreja K, Levine J, Blanton R, Hill NS, Karas RH. Biventricular remodeling in murine models of right ventricular pressure overload. PLoS One. 2013;8:e70802.
28. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, Walker C, Westwick J, Thomas M. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;184:1171-1182.
29. Urashima T, Zhao M, Wagner R, Fajardo G, Farahani S, Quertermous T, Bernstein D. Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis. Am J Physiol Heart Circ Physiol. 2008;295:H1351-H1368.
30. She X, Matsuno F, Harada N, Tsai H, Seon BK. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer. 2004;108:251-257.
31. Rockman HA, Ono S, Ross RS, Jones LR, Karimi M. Molecular and physiological alterations in murine ventricular dysfunction. Proc Natl Acad Sci USA. 1994;91:2694-2698.
32. Kass DA, Yamazaki T, Burkhoff D, Maughan WL, Sagawa K. Determination of left ventricular end-systolic pressure-volume relationships by the conductance (volume) catheter technique. Circulation. 1986;73:586-595.
33. Georgescu SP, Aronovitz MJ, Iovanna JL, Patten RD, Kyriakis JM, Goruppi S. Decreased metalloprotease 9 induction, cardiac fibrosis and higher autophagy after pressure overload in mice lacking the transcriptional regulator p8. Am J Physiol Cell Physiol. 2011;301:C1046-C1056.
34. Patten RD, Pourati I, Aronovitz MJ, Alsheikh-Ali A, Eder S, Force T, Mendelsohn ME, Karas RH. 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail. 2008;14:245-253.
35. Kapur NK, Deming CB, Kapur S, Bian C, Champion HC, Donahue JK, Kass DA, Rade JJ. Hemodynamic modulation of endocardial thromboresistance. Circulation. 2007;115:67-75.
36. Neuss M, Regitz-Zagrosek V, Hildebrandt A, Fleck E. Isolation and characterisation of human cardiac fibroblasts from explanted adult hearts. Cell Tissue Res. 1996;286:145-153.
37. White M, Montezano AC, Touyz RM. Angiotensin II signalling and calcineurin in cardiac fibroblasts: differential effects of calcineurin inhibitors FK506 and cyclosporine A. Ther Adv Cardiovasc Dis. 2012;6:5-14.
38. Zaffran S, Kelly RG, Meilhac SM, Buckingham ME, Brown NA. Right ventricular myocardium derives from the anterior heart field. Circ Res. 2004;95:261-268.
39. Ricci M, Mohapatra B, Urbiztondo A, Birusingh RJ, Morgado M, Rodriguez MM, Lincoln J, Vatta M. Differential changes in TGF-b/BMP signaling pathway in the right ventricular myocardium of newborns with hypoplastic left heart syndrome. J Card Fail. 2010;16:628-634.
40. Bristow MR, Zisman LS, Lowes BD, Abraham WT, Badesch DB. The pressureoverloaded right ventricle in pulmonary hypertension. Chest. 1998;114:101S-106S.
41. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease. I. Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation. 2008;117:1436-1448.
42. Dell'Italia LJ, Starling MR, Crawford MH, Boros BL, Chaudhuri TK. Right ventricular infarction: identification by hemodynamic measurements before and after volume loading and correlation with noninvasive techniques. J Am Coll Cardiol. 1984;4:931-939.
43. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, Dumur CI, Fawcett P, Voelkel NF, Natarajan R. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol. 2011;45:1239-1247.
44. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation. 2009;120:1951-1960.
45. Rowell J, Koitabashi N, Kass DA. TRP-ing up heart and vessels: canonical transient receptor potential channels and cardiovascular disease. J Cardiovasc Transl Res. 2010;3:516-524.
46. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res. 2011;89:744-753.
47. Berry JM, Le V, Rotter D, Battiprolu PK, Grinsfelder B, Tannous P, Burchfield JS, Czubryt M, Backs J, Olson EN, Rothermel BA, Hill JA. Reversibility of adverse, calcineurin-dependent cardiac remodeling. Circ Res. 2011;109:407-417.
48. Tewari SG, Bugenhagen SM, Wang Z, Schreier DA, Carlson BE, Chesler NC, Beard DA. Analysis of cardiovascular dynamics in pulmonary hypertensive C57BL6/J mice. Front Physiol. 2013;4:355.
49. Kögler H, Hartmann O, Leineweber K, van Nguyen P, Schott P, Brodde OE, Hasenfuss G. Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat. Circ Res. 2003;93:230-237.
50. Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomycininduced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol. 2008;294:L24-L33.
51. Saggar R, Khanna D, Vaidya A, Derhovanessian A, Maranian P, Duffy E, Belperio JA, Weigt SS, Dua S, Shapiro SS, Goldin JG, Abtin F, Lynch JP III, Ross DJ, Forfia PR, Saggar R. Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. Thorax. 2014;69:123-129.
52. Vitarelli A, Barillá F, Capotosto L, D'Angeli I, Truscelli G, De Maio M, Ashurov R. Right ventricular function in acute pulmonary embolism: a combined assessment by three-dimensional and speckle-tracking echocardiography. J Am Soc Echocardiogr. 2013;13:S0894-S00897.
53. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res. 2012;18:4820-4829.
54. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, Tsai H, Haruta Y. Endoglin-targeted cancer therapy. Curr Drug Deliv. 2011;8:135-143.